Purine nucleoside phosphorylase gene therapy for human malignanc

Details Purine nucleoside phosphorylase gene therapy for human malignanc Purine nucleoside phosphorylase gene therapy for human malignanc

1997-06-24

2000-01-25

Campell, Bruce R.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

4353201, A61K 4800, C12N 1500

Patent

active

060178965

ABSTRACT:
The present invention provides a method of killing replicating or non-replicating, transfected or transduced mammalian cells and bystander cells, comprising: (a) transfecting or transducing mammalian cells with a nucleic acid encoding a non-human purine cleavage enzyme; and (b) contacting the transfected or transduced cells with an effective amount of a substrate for the purine cleavage enzyme, wherein the substrate is non-toxic to mammalian cells and is cleaved by the enzyme to yield a purine toxic to the targeted mammalian cells and bystander cells, to kill the mammalian cells expressing the enzyme and the bystander cells. Further provided is a vector comprising a DNA sequence coding for a non-human purine nucleoside phosphorylase protein and the vector is capable of replication and/or expression in a host which comprises, in operable linkage: a) optionally, an origin of replication; b) a promoter; and c) a DNA sequence coding for said protein.

REFERENCES:
patent: 5552311 (1996-09-01), Sorscher et al.
DM Nelson et al Gene 113:215-221, 1992.
Liposomes: A Practical Approach, edited by R.R.C. New, The Practical Apprh Series, series editors: D. Rickwood and B.D. Hames, Oxford University Press, 1990 (complete book).
TANG et al. (1992) The nucleotide sequence of purine nucleoside phosphorylase gene from Entrobacter aerogenes W8401. Gongye Weishengwu, 22:1.
TANG et al. (1989) Cloning and expression of the Enterobacter aerogens W8401 purine nucleoside phosphorylase Gongye Weishengwu, 19:1-5.
ALLEN (1989) Stealth(TM) Liposomes: Avoiding Reticuleondothelial uptake. Liposomes in the Therapy of Infectious Diseases and Cancer, pp. 405-415.
ANDERSON (1992) Human Gene Therapy. Science, 256:808-813.
BAGSHAWE (1989) Towards generating cytotoxic agents at cancer sites. J. Cancer, 60:275-281.
BALZARINI et al. (1993) J. Biol. Chem., 268(9):6332-6337.
BARANKIEWICZ and JEZEWSKA (1976) Inosine-guanosine and adenosine phosphorylase activities in hepatopancreas of helix pomatia (gastropoda). Comp. Biochem. Physiol., vol. 54B, pp.239-242.
BENNETT et al. (1984) Mode of action of a-amino-6-chloro-1-deazapurine. Biochemical Pharmacology, vol. 33, No. 2, ppl 261-271.
BOHMAN et al. (1983) Mechanism of cytostatic action of novel 5-(Thien-2-yl) and 5-Furan-2yl)-substituted pyrimidine nucleoside analogues against tumor cells transfected by the thymidine kinase gene of herpes simplex virus. The Journal of Biological Chemistry, vol. 269, No. 11, ppl. 8036-8043.
BROCKMAN et al. (1980) Metabolism and chemotherapeutic activity of 9-.beta.-D-Arabinofuranosyl-2-fluroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Research, 40:3610-3615.
BRUCE and MEEKER (1976) J. Natl. Cancer Inst., 38:401-405.
BURLAND et al. (1995) Analysis of the Escherichia coli genome VI:DNA sequence of the region from 92.8 through 100 minutes. Necleic Acids Research, vol. 23, No. 12, pp. 2105-2119.
CARSON et al. (1980) Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl. Acad. Sci. USA, vol. 77, No. 11, pp. 6865-6869.
COLLIER (1988) Structure-activity relationships in and Pseudomonas aeruginosa exc. In Immuntoxins, A.E. Frankel, Ed. (Kluwer Academic Publishers, Boston), pp. 25-35.
CONNERS (1995) The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Therapy, 2:702-709.
CULVER et al. (1991) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Proc. Natl. Acad. Sci. USA, 88:3155-3159.
CULVER et al. (1992) Lymphocytes as cellular vehicles for gene therapy in mouse and man. Science, 256:1550-1552.
CULVER et al. (1994) Gene therapy for cancer. Trends in Genetics, 10:174-178.
CURIEL et al. (1992) High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylsine complexes. Hum. Gene Ther., 3:147-154.
DA COSTA et al. (1996) Converting cancer genes into killer genes. Proc. Natl. Acad. Sci. USA, 93:4192-4196.
DADONNA et al. (1986) Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. The Journal of Biological Chemistry, vol. 261, No. 25, Issue of Sep. 5, pp. 11667-11673.
DEBS et al. (1987) Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes. Am. Rev. Respir. Dis., 135:731-737.
DEWEY and KIDDER (1973) Partial purification and properties of a nucleoside hydrolase from crithidia. Archives of Biochemistry and Biophysics, 157:380-387.
DOSKOCIL and HOLY (1977) Specificity of purine nucleoside phosphorylase from Escherichia coli. Collection Czechoslov. Chem. Commun., 42:370-383.
DYKES et al. (1992) Development of human tumor zenograft models for in vivo evaluation of new antitumor drugs. Contri. Oncol. Basel, Karger, 42:1-22.
EALICK et al. (1990) Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution. The Journal of Biological Chemistry, vol. 265, No. 3, pp. 1812-1820.
FOX et al. (1996) Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Therapy, 9:173-178.
FREEMAN et al. (1996) In situ use of suicide genes for cancer therapy. Seminars in Oncology, 23:31-45.
FREIREICH et al. (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemotherapy Reports, vol. 50, No. 4. pp. 219-244.
FREIDMANN (1989) Progress toward human gene therapy. Science, 244:1275-1281.
GABIZON and PAPAHADIOPOULOS (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Sci. USA, 85:6949-6953.
GARVER et al. (1994) Strategy for achieving selective killing of carcinomas. Gene Therapy I., 46-50.
GAY (1984) Construction and characterization of an Escherichia coli strain with a uncI mutations. J. Bacteriol, 158:820-825.
GHODA et al. (1988) Substrate specificities of 5'-deoxy-5'methylthioadenosine phosphorylase from Trypanosoma brucei brucei and mammalian cells. Molecular and Biochemical Parasitology, 27:109-118.
GIEBEL et al. (1991) Organization and nucleotide sequences of the human tyrosinase gene and a truncated tyrosinase-related segment. Genomics, 9:435-445.
GUTTERIDGE and DAVIES (1981) Enzymes of purine salvage in trypanosoma cruzi. FEBS Letters, vol. 127, No. 2, pp. 21-24.
HATANKA et al. (1975) Adenine formation from adenosine by mycoplasmas: adenosine phosphorylase activity. Proc. Natl. Acad. Sci. USA, 72:1401-1405.
HERSHFIELD et al. (1991) Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl. Acad. Sci. USA, 88:7185-7189.
HEYWORTH et al. (1982) Purine metabolism in trichomonas vaginalis. FEBS Letters, vol. 1, No. 1, pp. 106-110.
HOOPER and SUBAK-SHARPE (1981) Metabolic cooperation between cells. Internat'l Rev. of Cytol., 69:45-104.
HOUSTON (1988) Introduction. In Immunotoxins. A.E. Frankel, Ed (Kluwer Academic Publishers, Boston) pp. 1-7.
HUANG et al. (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Research, 52:6774-6781.
HUBER et al. (1991)Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Acad. Sci. USA, 88:8039-8043.
HUGHES et al. (1995) Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Research, 55:3339-3345.
JENSEN (1978) Two purine nucleoside phosphorylases in bacillus subtills purification and some properties of the adenosine-specific phosphorylase. Biochimica et Biophysics Acta, 525:346-356.
JENSEN and NYGAARD (1975) Purine nucleoside phosphorylase from Escherichia coli and Salmonella typhimurium. Eur. J. Biochem., 51:253-265.
JENUTH and SNYDER (1991) Nucleotide sequence of murine purine nucleoside phosphorylase cDNA. Nucleic

Affiliated with

Also associated with

Rating

Purine nucleoside phosphorylase gene therapy for human malignanc does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Purine nucleoside phosphorylase gene therapy for human malignanc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine nucleoside phosphorylase gene therapy for human malignanc will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2316021